Display options
Cite
Cybula M, Wang L, Wang L, et al. Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research. Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246288.
Cybula, M., Wang, L., Wang, L., Drumond-Bock, A. L., Moxley, K. M., Benbrook, D. M., Gunderson-Jackson, C., Ruiz-Echevarria, M. J., Bhattacharya, R., Mukherjee, P., & Bieniasz, M. (2021). Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research. Cancers, 13(24), . https://doi.org/10.3390/cancers13246288
Cybula, Magdalena, et al. "Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246288
Cybula M, Wang L, Wang L, Drumond-Bock AL, Moxley KM, Benbrook DM, Gunderson-Jackson C, Ruiz-Echevarria MJ, Bhattacharya R, Mukherjee P, Bieniasz M. Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research. Cancers (Basel). 2021 Dec 15;13(24). doi: 10.3390/cancers13246288. PMID: 34944908.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Dec 15;13(24). doi: 10.3390/cancers13246288.

Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research.

Cancers

Magdalena Cybula, Lin Wang, Luyao Wang, Ana Luiza Drumond-Bock, Katherine M Moxley, Doris M Benbrook, Camille Gunderson-Jackson, Maria J Ruiz-Echevarria, Resham Bhattacharya, Priyabrata Mukherjee, Magdalena Bieniasz

Affiliations

  1. Aging and Metabolism Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
  2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
  3. Department of Pathology, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.

PMID: 34944908 DOI: 10.3390/cancers13246288

Abstract

(1) Background. PDX models have become the preferred tool in research laboratories seeking to improve development and pre-clinical testing of new drugs. PDXs have been shown to capture the cellular and molecular characteristics of human tumors better than simpler cell line-based models. More recently, however, hints that PDXs may change their characteristics over time have begun to emerge, emphasizing the need for comprehensive analysis of PDX evolution. (2) Methods. We established a panel of high-grade serous ovarian carcinoma (HGSOC) PDXs and developed and validated a 300-SNP signature that can be successfully utilized to assess genetic drift across PDX passages and detect PDX contamination with lymphoproliferative tissues. In addition, we performed a detailed histological characterization and functional assessment of multiple PDX passages. (3) Results. Our data show that the PDXs remain largely stable throughout propagation, with marginal genetic drift at the time of PDX initiation and adaptation to mouse host. Importantly, our PDX lines retained the major histological characteristics of the original patients' tumors even after multiple passages in mice, demonstrating a strong concordance with the clinical responses of their corresponding patients. (4) Conclusions. Our data underline the value of defined HGSOC PDXs as a pre-clinical tumor model.

Keywords: ovarian cancer; patient-derived xenograft; tumor model

References

  1. Nature. 2011 Jun 29;474(7353):609-15 - PubMed
  2. Lab Invest. 2018 Jul;98(7):947-956 - PubMed
  3. Breast Cancer Res. 2017 Dec 06;19(1):130 - PubMed
  4. Oncotarget. 2016 Feb 16;7(7):7993-8005 - PubMed
  5. Sci Rep. 2020 Apr 21;10(1):6688 - PubMed
  6. Muscle Nerve. 2009 Nov;40(5):867-71 - PubMed
  7. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3290-4 - PubMed
  8. J Clin Oncol. 2009 Mar 20;27(9):1419-25 - PubMed
  9. Sci Rep. 2016 Mar 01;6:22172 - PubMed
  10. Nat Med. 2011 Oct 23;17(11):1514-20 - PubMed
  11. Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3921-6 - PubMed
  12. Genes Cancer. 2016 May;7(5-6):169-81 - PubMed
  13. Nature. 2008 Dec 4;456(7222):593-8 - PubMed
  14. Cancer Res. 2013 Aug 1;73(15):4885-97 - PubMed
  15. Sci Rep. 2015 Mar 30;5:9447 - PubMed
  16. Front Oncol. 2013 Dec 04;3:295 - PubMed
  17. Nucleic Acids Res. 2008 Apr;36(7):2446-56 - PubMed
  18. Ann Oncol. 2017 Oct 1;28(10):2595-2605 - PubMed
  19. Cancer Res. 2014 Dec 1;74(23):6980-90 - PubMed
  20. Clin Exp Immunol. 2013 Dec;174(3):372-88 - PubMed
  21. PeerJ. 2019 Mar 28;7:e6586 - PubMed
  22. FASEB J. 2005 Mar;19(3):434-6 - PubMed
  23. J Vis Exp. 2016 Jul 29;(113): - PubMed
  24. J Vis Exp. 2010 Aug 17;(42): - PubMed
  25. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18708-13 - PubMed
  26. J Clin Oncol. 2009 Jun 1;27(16):2686-91 - PubMed
  27. PLoS One. 2016 Jan 05;11(1):e0145100 - PubMed
  28. Oncotarget. 2015 Jun 30;6(18):16059-68 - PubMed
  29. Nat Med. 2015 Nov;21(11):1318-25 - PubMed
  30. J Hum Genet. 2002;47(11):561-6 - PubMed
  31. Cancer Res. 2002 Oct 15;62(20):5828-34 - PubMed
  32. Br J Cancer. 2001 May 18;84(10):1424-31 - PubMed
  33. Cancer Res Treat. 2017 Oct;49(4):915-926 - PubMed
  34. Nat Genet. 2017 Nov;49(11):1567-1575 - PubMed
  35. J Transl Med. 2020 Aug 6;18(1):307 - PubMed
  36. Nat Rev Cancer. 2010 Nov;10(11):803-8 - PubMed
  37. Sci Rep. 2015 Oct 06;5:14495 - PubMed
  38. J Ovarian Res. 2009 Oct 13;2:14 - PubMed
  39. Mol Oncol. 2014 May;8(3):656-68 - PubMed
  40. Oncotarget. 2016 Sep 13;7(37):60475-60490 - PubMed
  41. Cold Spring Harb Protoc. 2015 Feb 02;2015(2):135-44 - PubMed
  42. Clin Pharmacol Ther. 2013 Sep;94(3):329-35 - PubMed
  43. Cancer Lett. 2014 Mar 1;344(1):13-19 - PubMed
  44. Exp Hematol. 2018 Nov;67:18-31 - PubMed
  45. Nat Commun. 2013;4:2126 - PubMed
  46. Neoplasia. 2017 Aug;19(8):628-636 - PubMed
  47. Mol Cells. 2016 Feb;39(2):77-86 - PubMed
  48. Int J Cancer. 2013 Jan 15;132(2):308-14 - PubMed
  49. Cancer Res Treat. 2018 Jan;50(1):1-10 - PubMed
  50. PLoS One. 2012;7(6):e39294 - PubMed
  51. PLoS One. 2016 Sep 09;11(9):e0160587 - PubMed
  52. Am J Transl Res. 2019 May 15;11(5):3128-3139 - PubMed
  53. Clin Cancer Res. 2017 Mar 1;23(5):1263-1273 - PubMed
  54. Dig Dis Sci. 2014 Jun;59(6):1169-79 - PubMed
  55. Chem Pharm Bull (Tokyo). 2018;66(3):225-230 - PubMed
  56. PLoS One. 2017 Aug 30;12(8):e0182855 - PubMed
  57. Curr Protoc Pharmacol. 2013 Mar;Chapter 14:Unit14.23 - PubMed
  58. Clin Cancer Res. 2010 Mar 1;16(5):1442-51 - PubMed
  59. J Transl Med. 2018 Nov 26;16(1):328 - PubMed
  60. Clin Cancer Res. 2015 Dec 15;21(24):5588-600 - PubMed
  61. Clin Cancer Res. 2014 Mar 1;20(5):1288-97 - PubMed
  62. Neoplasia. 2015 Sep;17(9):735-741 - PubMed
  63. J Cancer. 2021 Jan 1;12(1):28-37 - PubMed
  64. J Immunol. 2015 Mar 15;194(6):2725-34 - PubMed
  65. Cancers (Basel). 2012 Aug 29;4(3):821-45 - PubMed
  66. Nat Rev Cancer. 2019 Feb;19(2):97-109 - PubMed
  67. Virchows Arch. 2001 Feb;438(2):154-8 - PubMed
  68. Int J Cancer. 2020 Apr 15;146(8):2078-2088 - PubMed
  69. Cancer Biol Med. 2021 Feb 15;18(1):184-198 - PubMed
  70. Nat Med. 2018 Nov;24(11):1752-1761 - PubMed
  71. Ann Oncol. 2012 Sep;23 Suppl 10:x118-27 - PubMed
  72. Cold Spring Harb Protoc. 2014 Jul 01;2014(7):694-708 - PubMed
  73. BMC Cancer. 2010 Jul 08;10:362 - PubMed

Publication Types

Grant support